Home>
US Stocks>
Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc share price today

(NBY)

Novabay Pharmaceuticals Inc share price is $0.58 & ₹49.12 as on 7 Dec 2024, 2.30 'hrs' IST

$0.58

▲

0.01

(1.25%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Novabay Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Novabay Pharmaceuticals Inc from India. Also see the sentimental analysis on Indian investors investing in Novabay Pharmaceuticals Inc. Get details on the Indian mutual funds that are investing in Novabay Pharmaceuticals Inc. Get Analyst recommendations and forecasts along with all the Novabay Pharmaceuticals Inc's financials.

Novabay Pharmaceuticals Inc share price movements

$0.57
$0.60
$0.58
1.72%
Downside
Day's Volatility :4.84%
Upside
3.17%
$0.36
$10.50
$0.58
37.74%
Downside
52 Weeks Volatility :96.56%
Upside
94.48%

Novabay Pharmaceuticals Inc Returns

Period	Novabay Pharmaceuticals Inc	Index (Russel 2000)
3 Months	25.72%	0.0%
6 Months	-79.58%	0.0%
1 Year	-94.17%	0.0%
3 Years	-99.91%	-22.1%

Novabay Pharmaceuticals Inc Key Statistics

in dollars & INR

Previous Close	$0.5758
Open	$0.57
Today's High	$0.599
Today's Low	$0.57
Market Capitalization	$2.8M
Today's Volume	$40.3K
52 Week High	$10.5
52 Week Low	$0.3611
Revenue TTM	$13.1M
EBITDA	$-5.0M
Earnings Per Share (EPS)	$-74.34
Profit Margin	-77.48%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-263.83%

How to invest in Novabay Pharmaceuticals Inc from India?

It is very easy for Indian residents to invest directly in Novabay Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novabay Pharmaceuticals Inc stock in both rupees (INR) and dollars (USD). Search for Novabay Pharmaceuticals Inc or NBY on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novabay Pharmaceuticals Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novabay Pharmaceuticals Inc shares which would translate to 1.460 fractional shares of Novabay Pharmaceuticals Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Novabay Pharmaceuticals Inc

89%

Period: Sep 8, 2024 to Dec 7, 2024. Change in 30 Days versus previous period

Search volume for Novabay Pharmaceuticals Inc on INDmoney from India has grown in the last 30 days as on Dec 8, 2024. 89% more investors are searching Novabay Pharmaceuticals Inc in the last 30 days versus the previous period.

Analyst Recommendation on Novabay Pharmaceuticals Inc

Buy

83%Buy

16%Hold

0%Sell

Based on 6 Wall street analysts offering stock ratings for Novabay Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Based on 6 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novabay Pharmaceuticals Inc

What analysts predicted

Upside of 542.24%

Current:

$0.58

Target:

$3.73

Insights on Novabay Pharmaceuticals Inc

Increasing Revenue
Revenue is up for the last 2 quarters, 2.4M → 2.44M (in $), with an average increase of 1.7% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -4.10M → -1.21M (in $), with an average increase of 53.8% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 48.1% return, outperforming this stock by 142.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 142.2%

Novabay Pharmaceuticals Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$12.5M	↓ 31.39%
Net Income	$-6.5M	↓ 11.59%
Net Profit Margin	-52.33%	↓ 11.72%

	FY19	Y/Y Change
Revenue	$6.6M	↓ 47.24%
Net Income	$-10.5M	↑ 60.23%
Net Profit Margin	-158.92%	↓ 106.59%

	FY20	Y/Y Change
Revenue	$9.9M	↑ 50.54%
Net Income	$-11.0M	↑ 5.26%
Net Profit Margin	-111.12%	↑ 47.8%

	FY21	Y/Y Change
Revenue	$8.4M	↓ 15.23%
Net Income	$-6.6M	↓ 40.58%
Net Profit Margin	-77.89%	↑ 33.23%

	FY22	Y/Y Change
Revenue	$14.4M	↑ 71.05%
Net Income	$-16.3M	↑ 147.98%
Net Profit Margin	-112.92%	↓ 35.03%

	FY23	Y/Y Change
Revenue	$14.7M	↑ 2.24%
Net Income	$-9.6M	↓ 40.73%
Net Profit Margin	-65.46%	↑ 47.46%

	Q2 FY23	Q/Q Change
Revenue	$4.6M	↑ 47.57%
Net Income	$-4.0M	↑ 131.86%
Net Profit Margin	-87.46%	↓ 31.79%

	Q3 FY23	Q/Q Change
Revenue	$3.3M	↓ 29.39%
Net Income	$-1.8M	↓ 56.42%
Net Profit Margin	-53.98%	↑ 33.48%

	Q4 FY23	Q/Q Change
Revenue	$3.7M	↑ 14.5%
Net Income	$-4.1M	↑ 133.81%
Net Profit Margin	-110.22%	↓ 56.24%

	Q1 FY24	Q/Q Change
Revenue	$2.6M	↓ 29.41%
Net Income	$-3.2M	↓ 21.76%
Net Profit Margin	-122.16%	↓ 11.94%

	Q2 FY24	Q/Q Change
Revenue	$2.4M	↓ 8.78%
Net Income	$-1.6M	↓ 50.68%
Net Profit Margin	-66.04%	↑ 56.12%

	Q3 FY24	Q/Q Change
Revenue	$2.4M	↑ 1.71%
Net Income	$-1.2M	↓ 23.53%
Net Profit Margin	-49.65%	↑ 16.39%

	FY18	Y/Y Change
Total Assets	$9.4M	↓ 7.12%
Total Liabilities	$4.4M	↓ 41.12%

	FY19	Y/Y Change
Total Assets	$11.2M	↑ 19.86%
Total Liabilities	$10.2M	↑ 132.52%

	FY20	Y/Y Change
Total Assets	$15.2M	↑ 35.81%
Total Liabilities	$2.9M	↓ 71.5%

	FY21	Y/Y Change
Total Assets	$24.0M	↑ 57.36%
Total Liabilities	$13.8M	↑ 372.84%

	FY22	Y/Y Change
Total Assets	$16.4M	↓ 31.61%
Total Liabilities	$5.8M	↓ 57.67%

	FY23	Y/Y Change
Total Assets	$9.0M	↓ 44.91%
Total Liabilities	$5.7M	↓ 2.14%

	Q2 FY23	Q/Q Change
Total Assets	$16.0M	↑ 7.98%
Total Liabilities	$7.4M	↑ 25.44%

	Q3 FY23	Q/Q Change
Total Assets	$12.9M	↓ 19.72%
Total Liabilities	$5.8M	↓ 21.89%

	Q4 FY23	Q/Q Change
Total Assets	$9.0M	↓ 29.71%
Total Liabilities	$5.7M	↓ 1.63%

	Q1 FY24	Q/Q Change
Total Assets	$5.4M	↓ 40.7%
Total Liabilities	$5.2M	↓ 9.14%

	Q2 FY24	Q/Q Change
Total Assets	$3.9M	↓ 26.73%
Total Liabilities	$4.5M	↓ 12.6%

	Q3 FY24	Q/Q Change
Total Assets	$3.9M	↓ 1.22%
Total Liabilities	$2.8M	↓ 38.24%

	FY18	Y/Y Change
Operating Cash Flow	$-5.6M	↓ 11.2%
Investing Cash Flow	$-44.0K	↓ 81.97%
Financing Cash Flow	$5.6M	↑ 2684.58%

	FY19	Y/Y Change
Operating Cash Flow	$-7.9M	↑ 42.4%
Investing Cash Flow	$-19.0K	↓ 56.82%
Financing Cash Flow	$11.7M	↑ 109.08%

	FY20	Y/Y Change
Operating Cash Flow	$-4.7M	↓ 40.46%
Investing Cash Flow	$-26.0K	↑ 36.84%
Financing Cash Flow	$9.8M	↓ 16.58%

	FY21	Y/Y Change
Operating Cash Flow	$-9.2M	↑ 94.7%
Investing Cash Flow	$-12.0M	↑ 46226.92%
Financing Cash Flow	$16.8M	↑ 71.98%

	FY22	Y/Y Change
Operating Cash Flow	$-6.7M	↓ 27.61%
Investing Cash Flow	$-112.0K	↓ 99.07%
Financing Cash Flow	$4.6M	↓ 72.4%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-1.8M	↑ 14.4%
Investing Cash Flow	$-15.0K	↑ 15.38%
Financing Cash Flow	$2.5M	-

Novabay Pharmaceuticals Inc Technicals Summary

Sell

Neutral

Buy

Novabay Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Novabay Pharmaceuticals Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novabay Pharmaceuticals Inc	-17.06%	-79.58%	-94.17%	-99.91%	-99.92%
Regeneron Pharmaceuticals, Inc.	-7.31%	-23.34%	-9.49%	15.35%	108.86%
Biontech Se	7.41%	21.29%	18.26%	-58.19%	324.43%
Alnylam Pharmaceuticals, Inc.	-9.23%	64.08%	47.33%	46.0%	106.67%
Vertex Pharmaceuticals Incorporated	-11.0%	-4.83%	29.09%	120.68%	108.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novabay Pharmaceuticals Inc	NA	NA	0.0	-3.26	-2.64	-0.39	NA	0.22
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novabay Pharmaceuticals Inc	Buy	$2.8M	-99.92%	NA	-77.48%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	108.86%	18.56	33.61%
Biontech Se	Buy	$28.5B	324.43%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	106.67%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	108.8%	32.84	-4.51%

About Novabay Pharmaceuticals Inc

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Organization	Novabay Pharmaceuticals Inc
Employees	24
CEO	Mr. Justin M. Hall Esq.
Industry	Health Technology

Management People of Novabay Pharmaceuticals Inc

Name	Title
Mr. Justin M. Hall Esq.	President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
Mr. Tommy Law	Controller, Interim CFO & Treasurer

Important FAQs about investing in Novabay Pharmaceuticals Inc from India :

What is Novabay Pharmaceuticals Inc share price today?

Novabay Pharmaceuticals Inc (NBY) share price today is $0.58.

Can Indians buy Novabay Pharmaceuticals Inc shares?

Yes, Indians can invest in the Novabay Pharmaceuticals Inc (NBY) from India.

With INDmoney, you can buy Novabay Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novabay Pharmaceuticals Inc at zero transaction cost.

How can I buy Novabay Pharmaceuticals Inc shares from India?

It is very easy to buy Novabay Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novabay Pharmaceuticals Inc be purchased?

Yes, you can buy fractional shares of Novabay Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Novabay Pharmaceuticals Inc stocks?

To start investing in Novabay Pharmaceuticals Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.